Brentuximab vedotin with chemotherapy for patients with previously untreated Stage III/IV classical hodgkin lymphoma: 5-Year update of the ECHELON-1 study
dc.contributor.author | Ramchandren, R. | |
dc.contributor.author | Dlugosz-Danecka, M. | |
dc.contributor.author | Connors, J. M. | |
dc.contributor.author | Radford, John A | |
dc.contributor.author | Illes, A. | |
dc.contributor.author | Picardi, M. | |
dc.contributor.author | Lech-Maranda, E. | |
dc.contributor.author | Feldman, T. | |
dc.contributor.author | Smolewski, P. | |
dc.contributor.author | Savage, K. J. | |
dc.contributor.author | Bartlett, N. L. | |
dc.contributor.author | Walewski, J. | |
dc.contributor.author | Zinzani, P. L. | |
dc.contributor.author | Hutchings, M. | |
dc.contributor.author | Munoz, J. | |
dc.contributor.author | Kim, W. S. | |
dc.contributor.author | Advani, R. | |
dc.contributor.author | Ansell, S. M. | |
dc.contributor.author | Gallamini, A. | |
dc.contributor.author | Alekseev, S. | |
dc.contributor.author | Lee, H. J. | |
dc.contributor.author | Liu, R. | |
dc.contributor.author | Little, M. | |
dc.contributor.author | Fenton, K. | |
dc.contributor.author | Fanale, M. | |
dc.contributor.author | Straus, D. J. | |
dc.date.accessioned | 2021-09-30T11:56:10Z | |
dc.date.available | 2021-09-30T11:56:10Z | |
dc.date.issued | 2021 | en |
dc.identifier.citation | Ramchandren R, Dlugosz-Danecka M, Connors JM, Radford J, Illes A, Picardi M, et al. Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study. Clinical Lymphoma Myeloma & Leukemia. 2021;21:S371-S. | en |
dc.identifier.uri | http://hdl.handle.net/10541/624631 | |
dc.description.abstract | Objective: Historically, nearly all relapses in classical Hodgkin lymphoma (cHL) occur within the fi rst 5 years of treatment (Radford et al., BMJ 1997;314:346). In ECHELON-1, brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) signifi cantly improved modifi ed progression-free survival (PFS) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients with stage III/IV cHL (Connors et al., NEJM 2018;378:331). We report updated effi cacy and safety results; median follow-up was 60.9 months. Design: This phase 3, open-label study (NCT01712490) randomized patients with previously untreated stage III/IV cHL to receive 6 cycles of A+AVD or ABVD. Patients underwent an interim positron emission tomography scan after cycle 2 (PET2). An exploratory analysis of PFS per investigator was conducted. Results: There were 664 and 670 patients randomized to receive A+AVD and ABVD, respectively. 64%, 62%, and 58% of patients had stage IV disease, extranodal involvement at diagnosis, and B symptoms, respectively. Five-year PFS was 82.2% (95% confi dence interval [CI]: 79.0–85.0) with A+AVD and 75.3% (95% CI: 71.7–78.5) with ABVD. Overall, PFS favored A+AVD (hazard ratio [HR]: 0.681; 95% CI: 0.534–0.867; P=0.002). PFS benefi ts were observed regardless of PET2 status and International Prognostic Score. Estimated 5-year PFS with A+AVD versus ABVD was 84.9% versus 78.9% in PET2-negative patients (HR: 0.663; 95% CI: 0.502–0.876; P=0.004), and 60.6% versus 45.9% in PET2-positive patients (HR: 0.702; 95% CI: 0.393–1.255; P=0.229). Treatment-emergent peripheral neuropathy (PN) resolved or improved in 85% (n=375/443) and 86% (n=245/286) of the patients with PN on A+AVD and ABVD, respectively. Secondary malignancies occurred in 19 and 29 patients with A+AVD and ABVD, respectively. A total of 131 female patients or partners of male patients reported a pregnancy; both arms showed similar proportions of ongoing pregnancies or live births. Conclusions: At 5 years, A+AVD still demonstrates clinically meaningful improvement in PFS versus ABVD, independent of PET2 status, with a manageable safety profi le, including resolution or improvement of PN. The PFS benefi t observed with A+AVD at this important milestone suggests that A+AVD is an attractive treatment option for all patients with previously untreated stage III/IV cHL | en |
dc.language.iso | en | en |
dc.title | Brentuximab vedotin with chemotherapy for patients with previously untreated Stage III/IV classical hodgkin lymphoma: 5-Year update of the ECHELON-1 study | en |
dc.type | Other | en |
dc.contributor.department | The University of Tennessee Graduate School of Medicine, Knoxville, Tennessee, USA | en |
dc.identifier.journal | Clinical Lymphoma Myeloma & Leukemia | en |
dc.description.note | en] |